The prevalence of anti-citrullinated protein antibodies is low in patients with coronary artery disease without RA; in those with RA, C-reactive protein levels may explain the antibody-mortality link.

Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Rheumatoid arthritis patients often don't notice disease flares until symptoms have already worsened substantially. As joint ...

A national cohort study shows rheumatoid arthritis remission rates in England and Wales have plateaued since 2018, with wide ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

Women are disproportionately affected by almost every major form of arthritis, and the gap isn’t small. The pattern shows up ...

The EU project ENDOTARGET aims to improve the quality of life of people with rheumatic diseases. As part of a population cohort analysis, preliminary analyses provided initial insights into the ...

Lynk Pharmaceuticals shares encouraging topline data from Phase III trials of Zemprocitinib, showing promise in treating rheumatoid arthritis patients effectively.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and ...